By Benjamin Chiou
Date: Tuesday 11 Jun 2024
(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but the long-term investment case is "still appealing", according to Shore Capital, which kept a 'buy' rating on the stock.
GSK announced on Tuesday it has started...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news